The Multiple Myeloma Research Foundation (MMRF) is sponsoring the CoMMpass trial (NCT01454297), which aims to define subsets of multiple myeloma (MM) patients according to their molecular profiles. In this interview, Benjamin Barwick, MD, of Emory University, Atlanta, GA, discusses his groups work analyzing the CoMMpass study data. This analysis aims to identify translocations that result in worse outcomes for myeloma patients, and study specimens from the trial to discover common epigenetic alterations, such as DNA methylation patterns, that contribute to high-risk MM. This interview was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
Analyzing genetic and epigenetic markers of high-risk multiple myeloma
